PharmStars的动态

The expression “Last but not Least” was never more true than when the startups in PharmStars' current cohort were joined last week by Mark T. Rutledge, PhD of Sumitomo Pharma America, Inc. (SMPA) for the final Fireside Chat of our Spring semester.?Mark visited our PharmaU program to engage our startups in a discussion about opportunities for digital health innovation at SMPA. At SMPA (as with many pharma), the landscape for digital health innovation continues to evolve.?Mark helped the startups understand how both internal and external forces are influencing change and the impact change is having on SMPA's appetite for innovation.?Though market conditions are dictating the need for heightened scrutiny on projects, Mark emphasized SMPA’s continues to focus on opportunities that will deliver value, save money, and help get therapies to the market quickly and to the patients who will benefit from them. SMPA is currently developing their promising oncology assets, which is a perfect fit with PharmStars' current cohort of startups focused on "Digital Innovations in Oncology." We are excited for Mark and his colleagues to meet our startups next month at our culminating Showcase Event where they will share their innovations with SMPA and our other pharma members. Thanks, Mark, for sharing your insights, wisdom and enthusiasm with our Spring cohort of startups.?We value your time and your partnership! #Startup #Accelerator #DigitalHealth #pharma #biopharma #innovation #acceleratorprogram #biopharma

That’s a wrap! Another exciting PharmStars Alumni Showcase for the books took place last week. PharmStars’ unique #DigitalHealth #accelerator doesn’t end for our startups after graduation from PharmaU. This event was yet another opportunity to engage our #pharma members, investors, press and fellow startup leaders. We thank all the attendees for joining us and for contributing - we’ve already heard about many follow-up conversations planned with our startups. Thanks to our pharma members who bring the hard questions and provide such encouraging support:?Alexion Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Pfizer, and Sumitomo Pharma America, Inc. Thanks also to representatives from these investor groups. Their interest and input help fuel the startups’ activities and priorities: Fusion Fund, Hikma Ventures, Innospark Ventures, and Touchdown Ventures. And thanks to the members of the press who joined us to help spread the word about these rapidly advancing companies. What achievements and accomplishments did these #PharmStarsAlumni from our Fall 2022 Cohort “Digital #Innovations in Real World Evidence” report at our Showcase? ?Raising millions in capital in a tough funding environment ?Receipt of many awards, prizes, and recognition ?Strengthening, expanding and/or pivoting their digital health products ?Publication of scientific papers and case studies? ?Partnerships with providers and big tech firms ?? Pharma deals galore! 9 with PharmStars members and 50 with other biopharma partners Stay tuned for another post with details on these PharmStars alumni startup milestones that were shared at the Showcase. If you want to become a PharmStars alumni or member, and participate in a future Showcase, check out www.Pharmstars.com for more information. Meredith Cohen Marcella Rogers Joanne Kamens, PhD #accelerator #innovation #DigitalHealth #startup #pharma #DigitalInnovation #healthcare #medtech #HealthIt #biopharma #oncology #entrepreneurship

????Austrian Biotech Innovators With Austria’s biotech ecosystem continually evolving, its contribution to global healthcare is set to grow exponentially. From breakthrough therapies to cutting-edge diagnostics, early-stage startups are pushing the boundaries of what’s possible. Backed by a robust ecosystem of academia, government, and industry collaboration, these innovators are setting the stage for the next big leap in healthcare. But it’s not just about invention—it’s about impact. These startups are tackling some of the world’s most pressing health challenges, striving to cut costs, improve patient outcomes, and expand treatment access on a global scale. ?? Read more about the Top 10 Early-Stage Life Sciences/Biotech Startups reshaping the future: https://lnkd.in/gF4pibuy ? Featured Startups: ? Sarcura – Daniela Buchmayr, Erwin Gorjup (Cell therapy manufacturing) ? HeartBeat.bio AG – Michael Krebs, Florian Fuchs (Cardiac drug discovery) ? a:head bio AG – Oliver Szolar, Madeline Lancaster (CNS drug discovery) ? VALANX Biotech – Michael Lukesch (Protein conjugation) ? Cellectric Biosciences – Terje Wimberger, Klemens Wassermann(Precision diagnostics) ? Biolyz – Marlon Millard (Non-invasive analytics) ? Solgate – Ariel Bensimon, Giulio Superti-Furga, Stefan Kubicek, and Georg Winter (Metabolic disease targeting) ? HD Immune – Stefan Bartl, Lionel Wightman (Huntington’s treatment) ? Phoenestra GmbH – Klaus Graumann(Cell therapy bioprocessing) ? Luminous Labs – Barbara Sekulovska, Thomas Lechner (Red light therapy) ? Key Investors Supporting BioTech Innovation: XYZ Ventures | xista science ventures | Nina Capital |CTI Life Sciences Fund | Tensor Ventures | Atrinum. Ventures AG | Austria Wirtschaftsservice | Austrian Angel Investor Association (aaia) ?? Explore more such startups on Zefyron's Startup and Investor Database : bit.ly/Zefyron ???Sign up for FREE: bit.ly/ZefyronFree #BiotechInnovation #LifeSciences #Healthcare #AustrianStartups

Are most accelerators acting as farm leagues for the startup scouting ecosystem? I just arrived at the Startup Lithuania conference to ask this question to panelists from the Plug and Play Tech Center, GameBCN and xEDU communities. Having supported ~300 startups scouted by the Mastercard Lighthouse program and Nordic Science Capital, I believe incubators play a pivotal role in talent development. Indeed, 5 of the top 10 biotechs of all time (ranked by peak market cap) were started in incubators: 1. Amgen ($177b) ? 2. Moderna ($170b) ? 3. Regeneron ($131b) 4. Vertex Pharmaceuticals ($120b) 5. BioNTech SE ($108b) 6. Genentech ($100b) ? 7. Gilead Sciences ($100b) ? 8. Illumina ($77b) ? 9. Celgene Pharma ($74b) 10. Biogen ($70b) What are your thoughts?

We are getting there! Thanks for the mention, Zefyron. Humbling and exciting to see that 1) Health in general is getting more and more prime time attention ? 2) #longevityNOW interventions like ours at Luminous Labs are now getting the spotlight and bigger masses are beginning to understand what it needs in healthspan and lifespan enhancement to succeed. ? . As Sergey Young says, there are four horizons in longevity: diagnostics, prevention, intervention and reversal. . So far, longevity is mainly seen as moonshots; hardcore biotechs and reversal actions that should make us live forever, maybe. Now this is changing and that is GREAT, and it is an honour for us at Luminous Labs to really be seen for what we do. . We are biotech at core, but in a way that already enables humans to experiment and experience our technology in the now; non-invasive, low risk and with so much more potential to explore. ?? . Solving mitochondrial dysfunction one step at a time. ?? Thanks for the support BIOGENA GROUP Science Park Graz (SPG) Steirische Wirtschaftsf?rderung SFG FFG Austrian Research Promotion Agency And to all the ones that are on the journey with us BEYOND GENOMiX Maximon - The Longevity Company Builder Longevity Investors and many many more

?? ?????? ???? ???????????? ?????? ???????????????????? ?????????????? ?????????????????? StartupBlink focuses on the Healthtech startup scene in the EU. The European Union has fostered the growth of highly impactful #Healthtech firms such as Biontech, Novartis, and AstraZeneca, along with unicorns like LetsGetChecked and ōURA. In 2023, 111 cities in the EU were evaluated for their Healthtech industry, showing a relatively stable trend compared to the previous year. However, there remain 170 cities yet to undergo such evaluation in this sector. Let's delve into the top 10 cities leading the way in this industry ?? https://lnkd.in/dP5k7RWe #digitalhealth #healthinnovation #lifesciences #pharma #biopharma #innovation #startups

?? Exciting PharmStars Pharma Member Fireside Chat Update: PharmStars’ Spring cohort of startups recently engaged in an insightful discussion with James Cronin from Alexion Pharmaceuticals, Inc.?Jim talked about his priorities in R&D Development IT, where they focus on fostering science and excellence in execution, to bring novel products to market. ?? In today's rapidly evolving pharma landscape it’s important to identify gaps in drug development and care delivery and to evaluate whether innovations like GenAI, robotics, and others can help.?Jim discussed emerging technologies and the impact they will have on the pharma industry, in the near and longer term. Jim also reminded our #startups the importance of patience and relationship building.?While the Alexion team may be enthusiastic about an idea, they must also assess if the innovation meets an immediate business need.?Understandably, Alexion must wait for the right time when their needs and a startup’s solutions fully align. While we know that it can take a bit of times for THOSE stars ?? to align, we’re excited for Jim and the Alexion team to meet OUR Pharm“Stars” this June at our culminating Showcase Event in Boston. Thanks, Jim, for sharing your time and insights with our Spring cohort.?We are delighted to be working in partnership with you and the Alexion team! #startups #digitalhealth #pharma #biopharma #innovation #accelerator #acceleratorprogram

?? ?? Big deal in the Life Sciences sector! ? ?? AstraZeneca has just acquired the French biotech company Amolyt Pharma for one billion dollars, a record deal in 2024 for a European startup! ? WE Life Sciences holds an indirect stake in Amolyt through the LSP6 fund in which we are involved. This success demonstrates several things: ??In the context of life sciences startups, both individual VCs and investor syndicates are crucial. VCs often bring specific sector expertise, while syndicates allow for raising larger amounts of capital and benefiting from a diversity of expertise and networks. Startups often seek out investor syndicates to secure sufficient funding to carry out expensive and long-term research and development projects, which are typical in the life sciences sector. The deal with Amolyt demonstrates this, as does the €128 million fundraising by the German biotech company Tubulis (the largest fundraising in 2024), which was participated in by the Fund+ fund, itself participated in by WE Life Sciences. ? The 'Asset Centric' strategy highlights the importance of maximizing value creation and controlling costs. With the total development cost of a molecule ranging between €500 million and €1 billion and a clinical success probability of only 10 to 15%, it's crucial for startups to tightly manage costs until reaching the value creation point. This point helps in de-risking the molecule and sets up a cost structure to support further value creation (known as the switch point). Amolyt Pharma has excellently managed this aspect. ? Amolyt Pharma has excellently managed this aspect enabling it to move from the IND package to positive phase 2 results in the space of 4 years. ? Read the article about the AstraZeneca/Amolyt deal in L'Echo. ? #innovation #pharma #lifesciences #venturecapital Gery Lefebvre Anne VEREECKE

PharmStars is the go-to #accelerator for startups looking to engage #pharma as clients. “PharmStars was one of the best and most practically useful of all the accelerators we've participated in,” said #PharmStarsAlumni, Nader Alaghband, CEO of Ampersand Health. Why? Because of our: ?? Personalized mentoring: Tailored guidance for your startup's success by a small team of former pharma executives (no big, volunteer network of mentors!) ?? Pharma curriculum: Comprehensive curriculum about how pharma works and how to engage them in deals ?? Pharma Fireside Chats: Hear from and ask questions of pharma champions from our members in an intimate setting ?? Showcase Event: In-person pitch presentation followed by private meetings with our pharma members PharmStars ?? is now accepting applications for our Fall 2024 cohort, focused on #startups with digital #innovations in #ClinicalTrials. ?? ?? ?? Apply on our website www. PharmStars.com by July 15, 2024 #venturecapital?#Investment?#entrepreneur?#Investors?#transformation #partnerships #businessdevelopment #bizdev #engagement #financing #funding #biopharma #healthcare #digitaltransformation #digitalinnovation, #remotemonitoring #patientexperience #digital #innovation #virtualtrials #acceleratorprogram #datacollection #RemotePatientMonitoring #RPM #datamanagement #VC #clinicaltrials #digitalhealth #startup #pharmaceutical #biotech #HIT #medtech #healthtech #HealthIT

Unlock your path to pharma success with the PharmStars accelerator! ?? Hear from new #PharmStarsAlumni Maciek Klein of Saventic Health (Warsaw, Poland) on how our 10-week, virtual #AcceleratorProgram transformed his startup: ? ?? INSIGHTS AND CONNECTIONS - “Joining the 6th PharmStars (Spring) cohort was amazing. We connected with exceptional colleagues, gained invaluable insights from mentors, and honed our focus on interpretable, multimodal biomarkers for future cancer care.” ? ?? ACCELERATE BUSINESS ?- “Highly recommendable for startups aiming for global growth, especially in the US. The #PharmaU program offered deep industry insights, engagement with digital health leaders, and expert coaching to refine our value proposition and pitch.” ? Don’t miss out on YOUR chance to learn about and connect with pharma. Apply now for our Fall cohort focused on “Digital Innovation in Clinical Trials”. ? ? Hurry, deadline is TONIGHT, JULY 15 at midnight ET! ? For details and to apply visit: www.PharmStars.com ? #venturecapital #Investment #entrepreneur #Investors #transformation #partnerships #businessdevelopment #bizdev #engagement #financing #funding #biopharma #healthcare #pharma #digitaltransformation #digitalinnovation #remotemonitoring #patientexperience #digital #innovation #virtualtrials #accelerator #acceleratorprogram #datacollection #RemotePatientMonitoring #RPM #datamanagement #VC #clinicaltrials #pharmaceutical #biotech #HIT #medtech #healthtech #HealthIT #digitalhealth #startup #Poland ? ?